Sudarshan Pharma Industries has approved the acquisition of a 9.5% stake in US-based MedTherapy Biotechnology, an oncology-focused cell and gene therapy firm. Promoters Hemal Mehta and Sachin Mehta are also participating as individual investors with 1.5% stakes each. The move is designed to facilitate the company's entry into the US market and expand its capabilities in advanced cancer treatment services. The deal is subject to RBI approval under FEMA regulations and is expected to be completed by March 2027.
Sudarshan Pharma Enters US Biotech Market via MedTherapy Stake
Sudarshan Pharma Industries has approved the acquisition of 24,23,675 shares in MedTherapy Biotechnology Inc.
The acquisition represents a 9.50% stake in the Boston-based cancer cell and gene therapy firm.
Reader Takeaway: Strategic entry into the US oncology market; completion hinges on pending RBI regulatory approvals by March 2027.
What just happened
Sudarshan Pharma Industries Limited (SPIL) has formally approved the acquisition of a 9.50% equity stake in MedTherapy Biotechnology Inc., a US-incorporated entity. The transaction involves a cash consideration, the specifics of which remain undisclosed. Alongside the company's investment, Chairman and MD Hemal Mehta, and Joint MD Sachin Mehta, will each acquire an individual 1.50% stake in the target company.
Why this matters
This investment marks a strategic expansion for Sudarshan Pharma into the high-growth sector of CAR-T Cell and Gene therapy. MedTherapy Biotechnology functions as a contract development and manufacturing organization (CDMO) with operations spanning Boston and a GMP facility in New Delhi. By securing this stake, SPIL aims to leverage MedTherapy’s existing distribution networks and customer contracts to establish a firmer footing in the US market.
What changes now
Following the board's approval, the deal now moves into the due diligence and regulatory compliance phase. Because this involves an overseas investment, the company must secure clearances from the Reserve Bank of India (RBI) under Foreign Exchange Management Act (FEMA) guidelines. The company has set a long-term target completion date of March 31, 2027.
Risks to watch
Investors should note that the transaction is conditional. Success depends on the timely receipt of regulatory approvals and the effective integration of international operations. Furthermore, as the financial consideration remains confidential, the immediate impact on the company’s balance sheet cannot be fully assessed at this stage.
What to track next
Watch for further disclosures regarding the final cash consideration amount and updates on the status of the RBI filing. Additionally, operational milestones regarding the integration of MedTherapy’s manufacturing capabilities into the broader SPIL service portfolio will be critical for long-term value creation.